Atom Therapeutics Co., Ltd

Quick facts

Phase 2 pipeline

• ABP-745 Dose A · Oncology
  ABP-745 is a bispecific antibody that targets and blocks PD-1 and CTLA-4 receptors.
• ABP-745 Dose B
• ABP-745 Dose C
  ABP-745 is a bispecific antibody that simultaneously engages two distinct molecular targets to modulate immune or disease-related pathways.

Phase 1 pipeline

• ABP-671 plus allopurinol
• ABP-745

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Atom Therapeutics Co., Ltd portfolio CI brief
• Atom Therapeutics Co., Ltd pipeline updates RSS